Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. Cocrystal structure of merged fragment, VK-0497, in site 2 of EBNA1.
  • Fig. S2. Cocrystal structure of VK-0941 bound in site 2 of EBNA1.
  • Fig. S3. Cocrystal structure of VK-1760 bound to EBNA1.
  • Fig. S4. Biacore sensorgrams of EBNA1-CAC with EBNA1 inhibitors.
  • Fig. S5. Biacore sensorgrams of EBNA1-CAC with VK-1760.
  • Fig. S6. HSQC NMR spectra with 15N-labeled EBNA1.
  • Fig. S7. Cell viability assays of VK-1850.
  • Fig. S8. Cell-based activity assay of acid compounds.
  • Fig. S9. Combination treatment of C17-PDX with VK-1850 and IR.
  • Fig. S10. Combination treatment of C15-PDX and C17-PDX with EBNA1 inhibitor and cisplatin.
  • Fig. S11. Plasma and tumor concentrations of VK-1850.
  • Fig. S12. Assay for drug resistance in cells treated long-term with EBNA1 inhibitors.
  • Fig. S13. Heat map analysis of cellular gene expression using the NanoString Tumor Progression Panel.
  • Fig. S14. Synthesis of VK-0497.
  • Fig. S15. Synthesis of 3-ethynyl-2-(1H-indol-6-yl)-benzoic acid methyl ester.
  • Fig. S16. Chemical structure of VK-1850.
  • Table S1. Data collection and refinement statistics of EBNA1 cocrystal structures.
  • Table S2. Primers for quantitative PCR DNA copy and ChIP assay.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Data file S1 (Microsoft Excel format). Original data for Fig. 3B.
  • Data file S2 (Microsoft Excel format). Original data for fig. S8B.
  • Data file S3 (Microsoft Excel format). Original data for Fig. 3E.
  • Data file S4 (Microsoft Excel format). Original data for Fig. 3G.
  • Data file S5 (Microsoft Excel format). Original data for fig. S12A.
  • Data file S6 (Microsoft Excel format). Original data for fig. S12B.
  • Data file S7 (Microsoft Excel format). Custom NanoString CodeSet sequences for EBV.
  • Data file S8 (Microsoft Excel format). Changes in gene expression after treatment with VK-1850 and VK-1727.